{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["biomarkers", "gene expression", "ovarian cancer", "protein expression"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35807169", "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "07", "Day": "04"}], "Language": ["eng"], "ELocationID": ["3888", "10.3390/jcm11133888"], "Journal": {"ISSN": "2077-0383", "JournalIssue": {"Volume": "11", "Issue": "13", "PubDate": {"Year": "2022", "Month": "Jul", "Day": "04"}}, "Title": "Journal of clinical medicine", "ISOAbbreviation": "J Clin Med"}, "ArticleTitle": "Identification of New Molecular Biomarkers in Ovarian Cancer Using the Gene Expression Profile.", "Abstract": {"AbstractText": ["Ovarian cancer is a common cause of death among women worldwide. The current diagnostic and prognostic procedures available for the treatment of ovarian cancer are either not specific or are very expensive. Gene expression profiling has proved to be a very effective tool in the exploration of new molecular markers in patients with ovarian cancer, although the link between such markers and patient survival and clinical outcomes is still elusive. We are looking for genes that may function in the development and progression of ovarian cancer. The aim of our study was to evaluate the expression of selected suppressor genes (ATM, BRCA1, BRCA2), proto-oncogenes (KRAS, c-JUN, c-FOS), pro-apoptotic genes (NOXA, PUMA), genes related to chromatin remodeling (MEN1), and genes related to carcinogenesis (NOD2, CHEK2, EGFR). Tissue samples from 30 normal ovaries and 60 ovarian carcinoma tumors were provided for analysis of the gene and protein expression. Gene expression analysis was performed using the real-time PCR method. The protein concentrations from tissue homogenates were determined using the ELISA technique according to the manufacturers' protocols. An increase in the expression level of mRNA and protein in women with ovarian cancer was observed for KRAS, c-FOS, PUMA, and EGFR. No significant changes in the transcriptional levels we observed for BRCA1, BRCA2, NOD2, or CHEK2. In conclusion, we suggest that KRAS, NOXA, PUMA, c-FOS, and c-JUN may be associated with poor prognosis in ovarian cancer."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinic of Operational Gynecology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznan, Poland."}], "LastName": "Olbromski", "ForeName": "Piotr J\u00f3zef", "Initials": "PJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinic of Operational Gynecology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznan, Poland."}], "LastName": "Pawlik", "ForeName": "Piotr", "Initials": "P"}, {"Identifier": ["0000-0001-5455-8315"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, Kolejowa 2, 62-064 Plewiska, Poland."}], "LastName": "Bogacz", "ForeName": "Anna", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinic of Operational Gynecology, Poznan University of Medical Sciences, Polna 33, 60-535 Poznan, Poland."}], "LastName": "Sajdak", "ForeName": "Stefan", "Initials": "S"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "J Clin Med", "NlmUniqueID": "101606588", "ISSNLinking": "2077-0383"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Doubeni C., Doubeni A., Myers A. Diagnosis and Management of Ovarian Cancer. Am. Fam. Physician. 2016;93:937\u2013944.", "ArticleIdList": ["27281838"]}, {"Citation": "Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394\u2013424. doi: 10.3322/caac.21492.", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Bhatla N., Denny L. FIGO cancer report 2018. Int. J. Gynaecol. Obstet. 2018;143:2\u20133. doi: 10.1002/ijgo.12608.", "ArticleIdList": ["10.1002/ijgo.12608", "30306587"]}, {"Citation": "Malani P.N. Harrison\u2019s principles of internal medicine. JAMA. 2012;308:1813\u20131814. doi: 10.1001/jama.308.17.1813-b.", "ArticleIdList": ["10.1001/jama.308.17.1813-b"]}, {"Citation": "Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A. Ovarian cancer. Lancet. 2014;384:1376\u20131388. doi: 10.1016/S0140-6736(13)62146-7.", "ArticleIdList": ["10.1016/S0140-6736(13)62146-7", "24767708"]}, {"Citation": "Salehi F., Dunfield L., Phillips K.P., Krewski D., Vanderhyden B.C. Risk factors for ovarian cancer: An overview with emphasis on hormonal factors. J. Toxicol. Environ. Health B Crit. Rev. 2008;11:301\u2013321. doi: 10.1080/10937400701876095.", "ArticleIdList": ["10.1080/10937400701876095", "18368558"]}, {"Citation": "Zhao L., Li Y., Zhang Z., Zou J., Li J., Wei R., Guo Q., Zhu X., Chu C., Fu X., et al. Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer. Biosci. Rep. 2020;27:BSR20202911. doi: 10.1042/BSR20202911.", "ArticleIdList": ["10.1042/BSR20202911", "PMC7677829", "33135729"]}, {"Citation": "Moreno C.S., Matyunina L., Dickerson E.B., Schubert N., Bowen N.J., Logani S., Benigno B.B., McDonald J.F. Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS ONE. 2007;2:e441. doi: 10.1371/journal.pone.0000441.", "ArticleIdList": ["10.1371/journal.pone.0000441", "PMC1859837", "17505532"]}, {"Citation": "Bowen N.J., Walker L.D., Matyunina L.V., Logani S., Totten K.A., Benigno B.B., McDonald J.F. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med. Genom. 2009;2:71. doi: 10.1186/1755-8794-2-71.", "ArticleIdList": ["10.1186/1755-8794-2-71", "PMC2806370", "20040092"]}, {"Citation": "Oliveira D.V.N.P., Prahm K.P., Christensen I.J., Hansen A., H\u00f8gdall C.K., H\u00f8gdall E.V. Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. Sci. Rep. 2021;11:5438. doi: 10.1038/s41598-021-84953-9.", "ArticleIdList": ["10.1038/s41598-021-84953-9", "PMC7940404", "33686173"]}, {"Citation": "Bogacz A., Miko\u0142ajczak P.\u0141., Wolek M., G\u00f3rska A., Szulc M., O\u017carowski M., Kujawski R., Czerny B., Wolski H., Karpi\u0144ski T.M., et al. Combined Effects of Methyldopa and Flavonoids on the Expression of Selected Factors Related to Inflammatory Processes and Vascular Diseases in Human Placenta Cells\u2014An In Vitro Study. Molecules. 2021;2:1259. doi: 10.3390/molecules26051259.", "ArticleIdList": ["10.3390/molecules26051259", "PMC7956652", "33652665"]}, {"Citation": "Amatori S., Persico G., Fanelli M. Real-time quantitative PCR array to study drug-induced changes of gene expression in tumor cell lines. J. Cancer Metastasis Treat. 2017;3:90\u201399. doi: 10.20517/2394-4722.2017.22.", "ArticleIdList": ["10.20517/2394-4722.2017.22"]}, {"Citation": "Liang H., Zhang J., Shao C., Zhao L., Xu W., Sutherland L.C., Wang K. Differential Expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. J. Exp. Clin. Cancer Res. 2012;31:36. doi: 10.1186/1756-9966-31-36.", "ArticleIdList": ["10.1186/1756-9966-31-36", "PMC3403968", "22537942"]}, {"Citation": "Santos M.M., Tannuri A.C.A., Coelho M.C.M., Goncalves J.O., Serafini S., Ferraz da Silva L.F., Tannuri U. Immediate expression of c-fos and c-jun mRNA in a model of intestinal autotransplantation and ischemia-reperfusion in situ. Clinics. 2015;70:373\u2013379. doi: 10.6061/clinics/2015(05)12.", "ArticleIdList": ["10.6061/clinics/2015(05)12", "PMC4449475", "26039956"]}, {"Citation": "Ishimine M., Lee H.C., Nakaoka H., Orita H., Kobayashi T., Mizuguchi K., Endo M., Inoue I., Sato K., Yokomizo T. The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer. Dis. Markers. 2018;2018:5280736. doi: 10.1155/2018/5280736.", "ArticleIdList": ["10.1155/2018/5280736", "PMC5831679", "29651325"]}, {"Citation": "Xiong H., Zhang J. Expression and clinical significance of ATM and PUMA gene in patients with colorectal cancer. Oncol. Lett. 2017;14:7825\u20137828. doi: 10.3892/ol.2017.7181.", "ArticleIdList": ["10.3892/ol.2017.7181", "PMC5755051", "29344228"]}, {"Citation": "Hu W.M., Zhang Q., Huang L.H., Mo Z.H., Long X.D., Yang Y.B., Yang W.J., Liu J., Jin P. Identification of Novel Variants in MEN1: A Study Conducted with Four Multiple Endocrine Neoplasia Type 1 Patients. Horm. Metab. Res. 2020;52:788\u2013795. doi: 10.1055/a-1147-1375.", "ArticleIdList": ["10.1055/a-1147-1375", "32299109"]}, {"Citation": "Wang L.Y., Sun X.J., Chen M., Zhao M.H. The expression of NOD2, NLRP3 and NLRC5 and renal injury in anti-neutrophil cytoplasmic antibody-associated vasculitis. J. Transl. Med. 2019;17:197. doi: 10.1186/s12967-019-1949-5.", "ArticleIdList": ["10.1186/s12967-019-1949-5", "PMC6560890", "31186034"]}, {"Citation": "Sunde R.A. mRNA transcripts as molecular biomarkers in medicine and nutrition. J. Nutr. Biochem. 2010;21:665\u2013670. doi: 10.1016/j.jnutbio.2009.11.012.", "ArticleIdList": ["10.1016/j.jnutbio.2009.11.012", "PMC3095209", "20303730"]}, {"Citation": "Ismail R.S., Baldwin R.L., Fang J., Browning D., Karlan B.Y., Gasson J.C., Chang D.D. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 2000;60:6744\u20136749.", "ArticleIdList": ["11118061"]}, {"Citation": "Tonin P.N., Hudsno T.J., Rodier F., Bossolasco M., Lee P.D., Novak J., Mandreson E.N., Provencher D., Mes-Masson A. Microarray analysis of gene expression mirrors the biology of ovarian cancer model. Oncogene. 2001;20:6617\u20136626. doi: 10.1038/sj.onc.1204804.", "ArticleIdList": ["10.1038/sj.onc.1204804", "11641787"]}, {"Citation": "Wong K.K., Cheng R.S., Mok S.C. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques. 2001;30:670\u2013675. doi: 10.2144/01303dd05.", "ArticleIdList": ["10.2144/01303dd05", "11252802"]}, {"Citation": "Roy R., Chun J., Powell S.N. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer. 2011;12:68\u201378. doi: 10.1038/nrc3181.", "ArticleIdList": ["10.1038/nrc3181", "PMC4972490", "22193408"]}, {"Citation": "Saha S., Mandal P., Ganguly S., Jana D., Ayaz A., Banerjee A., Chouhan R., Sarkar D.K. Decreased expression of BRCA2 accelerates sporadic breast cancer progression. Indian J. Surg. Oncol. 2015;6:378\u2013383. doi: 10.1007/s13193-015-0449-1.", "ArticleIdList": ["10.1007/s13193-015-0449-1", "PMC4809839", "27065665"]}, {"Citation": "Tsibulak I., Wieser V., Degasper C., Shivalingaiah G., Wenzel S., Sprung S., Lax S.F., Marth C., Fiegl H., Zeimet A.G. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer. Br. J. Cancer. 2018;119:683\u2013692. doi: 10.1038/s41416-018-0217-4.", "ArticleIdList": ["10.1038/s41416-018-0217-4", "PMC6173779", "30111871"]}, {"Citation": "Gudas J.M., Nguyen H., Li T., Cowan K.H. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res. 1995;55:4561\u20134565.", "ArticleIdList": ["7553629"]}, {"Citation": "Egawa C., Miyoshi Y., Taguchi T., Tamaki Y., Noguchi S. High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients. Int. J. Cancer. 2002;98:879\u2013882. doi: 10.1002/ijc.10231.", "ArticleIdList": ["10.1002/ijc.10231", "11948466"]}, {"Citation": "Abdel-Fatah T.M.A., Arora A., Moseley P., Coveney C., Perry C., Johnson K., Kent C., Ball G., Chan S., Madhusudan S. ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin. 2014;2:10\u201317. doi: 10.1016/j.bbacli.2014.08.001.", "ArticleIdList": ["10.1016/j.bbacli.2014.08.001", "PMC4633921", "26674120"]}, {"Citation": "Feng X., Li H., Dean M., Wilson H.E., Kornaga E., Enwere E.K., Tang T., Paterson A., Lees-Miller S.P., Magliocco A.M., et al. Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer. Breast Cancer Res. 2015;17:65. doi: 10.1186/s13058-015-0575-2.", "ArticleIdList": ["10.1186/s13058-015-0575-2", "PMC4453198", "25935535"]}, {"Citation": "Han J., Flemington C., Houghton A.B., Gu Z., Zambetti G.P., Lutz R.J., Zhu L., Chittenden T. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc. Natl. Acad. Sci. USA. 2001;98:11318\u201311323. doi: 10.1073/pnas.201208798.", "ArticleIdList": ["10.1073/pnas.201208798", "PMC58727", "11572983"]}, {"Citation": "Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., Cocito A., Amati B. Genomic targets of the human c-Myc protein. Genes Dev. 2003;17:1115\u20131129. doi: 10.1101/gad.1067003.", "ArticleIdList": ["10.1101/gad.1067003", "PMC196049", "12695333"]}, {"Citation": "Reimertz C., Kogel D., Rami A., Chittenden T., Prehn J.H. Gene expression during ER stress-induced apoptosis in neurons: Induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway. J. Cell Biol. 2003;162:587\u2013597. doi: 10.1083/jcb.200305149.", "ArticleIdList": ["10.1083/jcb.200305149", "PMC2173793", "12913114"]}, {"Citation": "Castedo M., Coquelle A., Vivet S., Vitale I., Kauffmann A., Dessen P., Pequignot M.O., Casares N., Valent A., Mouhamad S., et al. Apoptosis regulation in tetraploid cancer cells. EMBO J. 2006;25:2584\u20132595. doi: 10.1038/sj.emboj.7601127.", "ArticleIdList": ["10.1038/sj.emboj.7601127", "PMC1478174", "16675948"]}, {"Citation": "Yu J., Zhang L. PUMA, a potent killer with or without p53. Oncogene. 2008;27:71\u201383. doi: 10.1038/onc.2009.45.", "ArticleIdList": ["10.1038/onc.2009.45", "PMC2860432", "19641508"]}, {"Citation": "Shibue T., Suzuki S., Okamoto H., Yoshida H., Ohba Y., Takaoka A., Taniguchi T. Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways. EMBO J. 2006;25:4952\u20134962. doi: 10.1038/sj.emboj.7601359.", "ArticleIdList": ["10.1038/sj.emboj.7601359", "PMC1618103", "17024184"]}, {"Citation": "Mahner S., Baasch C., Schwarz J., Hein S., Wolber L., Janicke F., Milde-Langosch K. C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br. J. Cancer. 2008;99:1269\u20131275. doi: 10.1038/sj.bjc.6604650.", "ArticleIdList": ["10.1038/sj.bjc.6604650", "PMC2570515", "18854825"]}, {"Citation": "Nelakurti D.D., Pappula A.L., Rajasekaran S., Miles W.O., Petreaca R.C. Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer. Cancers. 2020;12:2616. doi: 10.3390/cancers12092616.", "ArticleIdList": ["10.3390/cancers12092616", "PMC7565326", "32937789"]}, {"Citation": "Ma X., Qiu Y., Sun Y., Zhu L., Zhao Y., Li T., Lin Y., Ma D., Qin Z., Sun C., et al. NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway. Cell Death Dis. 2020;11:174. doi: 10.1038/s41419-020-2368-5.", "ArticleIdList": ["10.1038/s41419-020-2368-5", "PMC7060316", "32144252"]}, {"Citation": "Xu D., Zhang S., Zhang S., Liu H., Li P., Yu L., Shang H., Hou Y., Tian Y. NOD2 maybe a biomarker for the survival of kidney cancer patients. Oncotarget. 2017;8:101489\u2013101499. doi: 10.18632/oncotarget.21547.", "ArticleIdList": ["10.18632/oncotarget.21547", "PMC5731890", "29254180"]}, {"Citation": "Stolarova L., Kleiblova P., Janatova M., Soukupova J., Zemankova P., Macurek L., Kleibl Z. CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate. Cells. 2020;9:2675. doi: 10.3390/cells9122675.", "ArticleIdList": ["10.3390/cells9122675", "PMC7763663", "33322746"]}, {"Citation": "Mehner C., Oberg A.L., Goergen K.M., Kalli K.R., Maurer M.J., Nassar A., Goode E.L., Keeney G.L., Jatoi A., Radisky D.C., et al. EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: Evaluation of patient cohort and literature review. Genes Cancer. 2017;8:589\u2013599. doi: 10.18632/genesandcancer.142.", "ArticleIdList": ["10.18632/genesandcancer.142", "PMC5511892", "28740577"]}, {"Citation": "Teplinsky E., Muggia F. EGFR and HER2: Is there a role in ovarian cancer? Transl. Cancer Res. 2015;4:107\u2013117."}, {"Citation": "C\u00eerstea A.E., Stepan A.E., M\u0103rg\u0103ritescu C., Z\u0103voi R.E., Olimid D.A., Simionescu C.E. The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors. Rom. J. Morphol. Embryol. 2017;58:1269\u20131273.", "ArticleIdList": ["29556616"]}, {"Citation": "Farrag M.S., Emarah Z., Elrefaie W., Farrag N.S., Hafez M.T., Abdelwahab K. EGFR and HER2 Expression in Primary Ovarian High-Grade Serous Carcinoma and Their Prognostic Value. Res. Oncol. 2021;17:9\u201316. doi: 10.21608/resoncol.2020.43021.1115.", "ArticleIdList": ["10.21608/resoncol.2020.43021.1115"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "6", "Day": "8"}, {"Year": "2022", "Month": "6", "Day": "28"}, {"Year": "2022", "Month": "6", "Day": "30"}, {"Year": "2022", "Month": "7", "Day": "9", "Hour": "1", "Minute": "17"}, {"Year": "2022", "Month": "7", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "10", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "7", "Day": "4"}], "PublicationStatus": "epublish", "ArticleIdList": ["35807169", "PMC9267752", "10.3390/jcm11133888", "jcm11133888"]}}], "PubmedBookArticle": []}